LI Kang Biomedical (6242) Monthly Revenue

Market: TPEx (OTC) · Industry: Biotech & Medical · 立康

LI Kang Biomedical (6242) reported revenue of NT$53 million for Oct 2026, -8.1% year on year and +26.4% from the previous month. Revenue for Jan–Oct 2026 was NT$457.5 million (-3.7% year on year).

In Oct 2026, it ranked No. 97 by revenue among 160 Biotech & Medical companies.

Monthly revenue chart

Oct 2024 NT$57.2 million24/10Nov 2024 NT$53.7 millionDec 2024 NT$53 millionJan 2025 NT$32.7 millionFeb 2025 NT$44 million25/02Mar 2025 NT$58.1 millionApr 2025 NT$56.5 millionMay 2025 NT$53.7 millionJun 2025 NT$54.4 million25/06Jul 2025 NT$42.1 millionAug 2025 NT$37.2 millionSep 2025 NT$38.9 millionOct 2025 NT$57.6 million25/10Nov 2025 NT$59.2 millionDec 2025 NT$54.8 millionJan 2026 NT$43.7 millionFeb 2026 NT$24.4 million26/02Mar 2026 NT$53.5 millionApr 2026 NT$54.1 millionMay 2026 NT$58 millionJun 2026 NT$49.9 million26/06Jul 2026 NT$42.1 millionAug 2026 NT$37 millionSep 2026 NT$41.9 millionOct 2026 NT$53 million26/10

Hover over (or tap) a bar to see that month’s revenue.

Monthly revenue history

MonthRevenueYoYMoM
Oct 2026NT$53 million-8.1%+26.4%
Sep 2026NT$41.9 million+7.6%+13.2%
Aug 2026NT$37 million-0.5%-12.0%
Jul 2026NT$42.1 million-0.1%-15.6%
Jun 2026NT$49.9 million-8.3%-14.1%
May 2026NT$58 million+7.9%+7.2%
Apr 2026NT$54.1 million-4.2%+1.1%
Mar 2026NT$53.5 million-7.9%+119.5%
Feb 2026NT$24.4 million-44.6%-44.2%
Jan 2026NT$43.7 million+33.6%-20.3%
Dec 2025NT$54.8 million+3.3%-7.4%
Nov 2025NT$59.2 million+10.2%+2.6%
Oct 2025NT$57.6 million+0.8%+48.1%
Sep 2025NT$38.9 million-20.7%+4.7%
Aug 2025NT$37.2 million-1.7%-11.6%
Jul 2025NT$42.1 million+4.3%-22.6%
Jun 2025NT$54.4 million+18.2%+1.2%
May 2025NT$53.7 million+1.9%-4.8%
Apr 2025NT$56.5 million+8.6%-2.9%
Mar 2025NT$58.1 million+4.1%+32.2%
Feb 2025NT$44 million+57.6%+34.5%
Jan 2025NT$32.7 million-17.9%-38.3%
Dec 2024NT$53 million-4.3%-1.3%
Nov 2024NT$53.7 million-9.5%-6.1%
Oct 2024NT$57.2 million+0.3%+16.5%

Jan–Oct 2026 cumulative: NT$457.5 million (-3.7% YoY)

History covers months since this site began collecting, plus prior-month and prior-year figures in each release. It grows every month.

Other Biotech & Medical companies

Compare with peers: LI Kang Biomedical vs PEC / LI Kang Biomedical vs Lotus Pharm / LI Kang Biomedical vs Bora

CompanyRevenueYoY
PEC6446NT$2.84 billion+102.0%
Lotus Pharm1795NT$2.13 billion-22.5%
Bora6472NT$1.99 billion+15.9%
Great Tree Pharmacy6469NT$1.67 billion+1.5%
EXCELSIOR4104NT$1.02 billion+38.6%
PEGAVISION6491NT$793 million+13.0%
Synmosa Biopharma4114NT$766.6 million+41.2%
Y.S.H.3705NT$749.4 million+4.4%

See also

← All Taiwan listed & OTC companies

Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16